Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426367 | 1.00 | ADRA2C (0.60) | ADRA2CDRD2DRD3MAPTMAPK1 | |
| SCHEMBL29586471 | 0.81 | DRD3 (0.50) | ADRA2CDRD2DRD3MAPTMAPK1 | |
| SCHEMBL23294808 | 0.81 | DRD3 (0.50) | ADRA2CDRD2DRD3MAPTMAPK1 | |
| SCHEMBL23294841 | 0.81 | ADRA2C (0.58) | ADRA2CDRD2DRD3MAPTMAPK1 | |
| SCHEMBL30350850 | 0.80 | KEAP1 (0.54) | MAPTMAPK1EGFRKMT2AKDM4E | |
| SCHEMBL19510747 | 0.80 | KEAP1 (0.54) | MAPTMAPK1EGFRKMT2AKDM4E | |
| SCHEMBL23277135 | 0.79 | ADRB1 (0.57) | DRD2DRD3LMNAHTR1ADRD4 | |
| SCHEMBL172953 | 0.78 | KEAP1 (0.57) | MAPTMAPK1EGFRLMNAKMT2A | |
| SCHEMBL173027 | 0.77 | ADRB1 (0.62) | ADRA2CDRD2DRD3MAPTMAPK1 | |
| SCHEMBL424507 | 0.77 | DRD2 (0.75) | ADRA2CDRD2DRD3MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541759-A | Novel method for preparing vortioxetine | MAGUS PHARMACEUTICAL (XIAMEN) CO LTD | 2016-05-04 | — | — | CN | claimed |
| US-20220347299-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | LightOx Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| CN-114127046-A | Fluorescence system for biological imaging and use thereof | 莱托克斯有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3921373-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | Lightox Limited (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| WO-2021009506-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | LightOx Limited (GB) | 2021-01-21 | — | — | WO | disclosed |
| CN-105541759-A | Novel method for preparing vortioxetine | MAGUS PHARMACEUTICAL (XIAMEN) CO LTD | 2016-05-04 | — | — | CN | disclosed |
| EP-2751108-B1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347299-A1 | FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF | SON, DNER, CASR | ADRA2C 3346/4885DRD2 497/4885DRD3 575/4885 |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | TK1, XDH, KYAT1 | ADRA2C 1251/4885DRD2 3009/4885DRD3 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.